Article Text

P158 Fluticasone furoate(FF)/vilanterol (VI) once daily improves night-time awakenings in asthma
  1. N Barnes1,
  2. L Yates1,
  3. MR Gibbs1,
  4. R Forth2
  1. 1GlaxoSmithKline Respiratory Global Franchise, London, UK
  2. 2PAREXEL International, Research Triangle Park, USA


Introduction and objectives FF/VI, the first once daily inhaled corticosteroid/long-acting ß2-agonist combination available for the treatment of asthma, has demonstrated a sustained 24 hour improvement in lung function and improvement in symptom-free 24 hour periods.

Methods Post-hoc analyses of diary card data from three Phase III studies were performed to examine whether there was an improvement in night-time awakening during the studies for those patients treated with the addition of vilanterol to fluticasone furoate. The diary card scale used is described below. Changes in night-time awakenings over the duration of the studies were analysed for percentage of patients with ≥50% symptom-free nights, including the time taken for 50% of patients to achieve 7 nights without symptoms.

Night-time Symptom Score:

0 = No symptoms during the night

1 = Symptoms causing me to wake once (or wake early)

2 = Symptoms causing me to wake twice or more (including waking early)

3 = Symptoms causing me to be awake for most of the night

4 = Symptoms so severe that I did not sleep at all

To be counted as symptom-free during the night the patient needed to record a score of 0.

Results The percentage of patients with ≥50% symptom-free nights was generally higher in patients treated with FF/VI compared to either FF or FP alone (Table below). The time (in days) for 50% of patients to achieve 7 nights without symptoms was achieved sooner with patients treated with FF/VI compared to FF alone (Table).

Conclusions In general, night-time awakenings improved over time in asthma patients with FF/VI and improved faster with FF/VI compared with FF or placebo.

Abstract P158 Table 1

Treatment comparisons for % patients with 50% symptom free nights over the study duration

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.